Roivant Sciences Ltd. ROIV

Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The readout gives Roivant (NASDAQ:ROIV) another late-stage pipeline opportunity shortly after the company won U.S. approval for Lisraya, its treatment for adults with dermatomyositis. READ ALSO: […]

Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140

Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that […]

Roivant Sciences (NasdaqGS: ROIV) reported positive Phase 2 PHocus trial results for mosliciguat in PH-ILD patients. The study showed statistically significant and clinically meaningful changes in pulmonary vascular resistance and six-minute walk distance measures. Management highlighted the PHocus findings at recent scientific conference presentations focused on pulmonary hypertension and interstitial lung disease. There is more to Roivant than the PHocus mosliciguat data investors are...

Roivant Sciences Ltd. (NASDAQ:ROIV) shares surged 18% on September 8 after the biotech company reported strong Phase 2 results for an experimental treatment for pulmonary hypertension. The positive topline results from the Phase 2 PHocus trial of Mosliciguat provide an important clinical validation for one of the company’s most promising pipeline assets. The candidate drug […]

The healthcare team dive into the latest data and emerging trends from the ESC Congress and ERS Congress.

Companies In The Article Are:QCOM,ROIV,BE and NVS

Investors rewarded three very different catalysts spanning artificial intelligence, biotechnology, and energy.

Roivant Sciences Ltd. (NASDAQ:ROIV) soared to a new all-time high on Tuesday after reporting stellar results from the clinical trial of its treatment candidate for pulmonary hypertension associated with interstitial lung disease (PH-ILD). In intra-day trading, the stock jumped to its highest price of $42.50 before trimming gains to end the session just up by […]

Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments.

Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.

Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus